Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review

被引:39
|
作者
Poyatos, Lourdes [1 ,2 ,3 ,4 ]
Pilar Perez-Acevedo, Ana [1 ,2 ,3 ,4 ]
Papaseit, Esther [1 ,2 ,3 ,4 ]
Perez-Mana, Clara [1 ,2 ,3 ,4 ]
Martin, Soraya [1 ,2 ]
Hladun, Olga [1 ,2 ,3 ,4 ]
Siles, Adria [2 ,5 ]
Torrens, Marta [3 ,4 ,6 ,7 ]
Paolo Busardo, Francesco [8 ]
Farre, Magi [1 ,2 ,3 ,4 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain
[2] Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain
[3] Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain
[4] Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain
[5] Hosp Badalona Germans Trias & Pujol, Pharm Dept, Badalona 08916, Spain
[6] Parc Salut Mar, Drug Addict Program, Inst Neuropsiquiatria, Barcelona 08003, Spain
[7] Inst Hosp del Mar Recerca Med PSMAR IMIM, Barcelona 08003, Spain
[8] Univ Politecn Marche, Dept Excellence Biomed Sci & Publ Hlth, I-60121 Ancona, Italy
来源
MEDICINA-LITHUANIA | 2020年 / 56卷 / 06期
关键词
oral cannabis; oral THC; medical use; cannabis edibles; pharmacokinetics; DELTA(9)-TETRAHYDROCANNABINOL THC; HEALTHY-VOLUNTEERS; MEDICINAL CANNABIS; PHARMACOKINETICS; PLASMA; BLOOD; DRONABINOL; MARIJUANA; PROFILE; SINGLE;
D O I
10.3390/medicina56060309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: Changes in cannabis legalization regimes in several countries have influenced the diversification of cannabis use. There is an ever-increasing number of cannabis forms available, which are gaining popularity for both recreational and therapeutic use. From a therapeutic perspective, oral cannabis containing Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is a promising route of administration but there is still little information about its pharmacokinetics (PK) effects in humans. The purpose of this systematic review is to provide a general overview of the available PK data on cannabis and THC after oral administration.Materials and Methods: A search of the published literature was conducted using the PubMed database to collect available articles describing the PK data of THC after oral administration in humans.Results: The literature search yielded 363 results, 26 of which met our inclusion criteria. The PK of oral THC has been studied using capsules (including oil content), tablets, baked goods (brownies and cookies), and oil and tea (decoctions). Capsules and tablets, which mainly correspond to pharmaceutical forms, were found to be the oral formulations most commonly studied. Overall, the results reflect the high variability in the THC absorption of oral formulations, with delayed peak plasma concentrations compared to other routes of administration.Conclusions: Oral THC has a highly variable PK profile that differs between formulations, with seemingly higher variability in baked goods and oil forms. Overall, there is limited information available in this field. Therefore, further investigations are required to unravel the unpredictability of oral THC administration to increase the effectiveness and safety of oral formulations in medicinal use.
引用
收藏
页码:1 / 28
页数:21
相关论文
共 50 条
  • [31] Psychomotor performance in relation to acute oral administration of Δ9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects
    Roser, Patrik
    Gallinat, Juergen
    Weinberg, Gordon
    Juckel, Georg
    Gorynia, Inge
    Stadelmann, Andreas M.
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2009, 259 (05) : 284 - 292
  • [32] Cannabis is more than simply Δ9-tetrahydrocannabinol
    Ethan B. Russo
    John M. McPartland
    Psychopharmacology, 2003, 165 : 431 - 432
  • [33] Psychomotor performance in relation to acute oral administration of Δ9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects
    Patrik Roser
    Jürgen Gallinat
    Gordon Weinberg
    Georg Juckel
    Inge Gorynia
    Andreas M. Stadelmann
    European Archives of Psychiatry and Clinical Neuroscience, 2009, 259
  • [34] Oral Fluid Cannabinoids in Chronic Cannabis Smokers during Oral Δ9-Tetrahydrocannabinol Therapy and Smoked Cannabis Challenge
    Lee, Dayong
    Vandrey, Ryan
    Mendu, Damodara R.
    Anizan, Sebastien
    Milman, Garry
    Murray, Jeannie A.
    Barnes, Allan J.
    Huestis, Marilyn A.
    CLINICAL CHEMISTRY, 2013, 59 (12) : 1770 - 1779
  • [35] Assay of Δ9-Tetrahydrocannabinol (THC) in oral fluid-evaluation of the OraSure Oral Specimen Collection Device
    Kauert, GF
    Iwersen-Bergmann, S
    Toennes, SW
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2006, 30 (04) : 274 - 277
  • [36] Acute and chronic e ff ects of? 9-tetrahydrocannabinol (THC) on cerebral blood fl ow: A systematic review
    Ogunbiyi, M. Olabisi
    Hindocha, Chandni
    Freeman, Tom P.
    Bloomfield, Michael A. P.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2020, 101
  • [37] Implications of Plasma Δ9-Tetrahydrocannabinol, 11-Hydroxy-THC, and 11-nor-9-Carboxy-THC Concentrations in Chronic Cannabis Smokers
    Karschner, Erin L.
    Schwilke, Eugene W.
    Lowe, Ross H.
    Darwin, W. David
    Herning, Ronald I.
    Cadet, Jean Lud
    Huestis, Marilyn A.
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2009, 33 (08) : 469 - 477
  • [38] The Effects of Δ9-Tetrahydrocannabinol (THC) Drug History on THC Taste and Place Conditioning
    Hempel, Briana
    Wakeford, Alison
    Clasen, Matthew
    Friar, Mary
    Riley, Anthony
    FASEB JOURNAL, 2016, 30
  • [39] Sublingual administration of Δ9-tetrahydrocannabinol/β-cyclodextrin complex increases the bioavailability of Δ9-tetrahydrocannabinol in rabbits
    Mannila, J
    Järvinen, T
    Järvinen, K
    Tervonen, J
    Jarho, P
    LIFE SCIENCES, 2006, 78 (17) : 1911 - 1914
  • [40] Evidence Considered in Determination of Cannabis Smoke and Δ9-Tetrahydrocannabinol (THC) as Causing Reproductive Toxicity (Developmental Endpoint)
    Campbell, M.
    Iyer, P.
    Kaufman, F.
    Kim, A.
    Moran, F.
    Niknam, Y.
    Wu, L.
    Sandy, M. S.
    Zeise, L.
    BIRTH DEFECTS RESEARCH, 2020, 112 (11): : 847 - 847